Nov. 8 at 7:51 AM
$CUPR From CEO:
Hi Peter,
Thank you for reaching out and for your continued support of Cuprina. I completely understand the concern regarding the recent share price and lower trading volume. Unfortunately, I can’t comment much on market movements, as they’re often influenced by factors outside of the company’s control.
That said, please don’t be too worried, we remain focused on executing our strategy and strengthening the fundamentals of the business. Progress continues steadily behind the scenes, and all we can do is stay committed to our plan and trust that the results will speak for themselves in time.
Regarding Dr. Sherman’s comment, yes, Cuprina is currently the second largest company in the global medical maggot therapy space. The largest is BioMonde, which operates mainly in Europe.
Thank you again for your patience and faith in what we’re building, it truly means a lot to the team.